[1] Asher, A., Van Dyk, K., Patel, S. K., Newman, R., Engle, J., Hutchison, N., & Padgett, L. (2017). Cancerrelated cognitive changes. Archives of Physical Medicine and Rehabilitation, 98(12), 2595-2596. http://dx.doi.org/10.1016/j.apmr.2017.05.011 

[2] Baghdadli, A., Arcuri, G. G., Green, C. G., Gauthier, L. R., Gagnon, P., & Gagnon, B. (2023). The fast cognitive evaluation (FaCE): A screening tool to detect cognitive impairment in patients with cancer. BMC Cancer, 23(1), 35. https://doi.org/10.1186/s12885-022-10470-1 

[3] Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998). Hopkins verbal learning test-revised: Normative data and analysis of inter-form and test-retest reliability. The Clinical Neuropsychologist, 12(1), 43-55. https://doi.org/10.1076/clin.12.1.43.1726 

[4] Candido, W., Eggen, A. C., Jalving, M., Bosma, I., Horinga, R. D., van Heuvelen, K. C., Hiltermann, T. J. N., Oosting, S., Racz, E., van der Klauw, M. M., Reyners, A. K. L., & Nuver, J. (2025). Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment. Journal for Immunotherapy of Cancer, 13(3), e011168. https://doi.org/10.1136/jitc-2024-011168 

[5] Castel, H., Denouel, A., Lange, M., Tonon, M. C., Dubois, M., & Joly, F. (2017). Biomarkers associated with cognitive impairment in treated cancer patients: Potential predisposition and risk factors. Frontiers in Pharmacology, 8, 138. https://doi.org/10.3389/fphar.2017.00138 

[6] Chen, H., Jia, H., Jiang, T., & Jia, Y. (2024). Effects of intraoperative blood glucose fluctuation and postoperative insulin resistance on cognitive dysfunction in elderly patients after thoracoscopic radical resection of lung cancer under general anesthesia. Tianjin Medical Journal, 52(2), 201-205. https://doi.org/10.11958/20230390 

[7] Cheng, Z., Qian, T., Yu, J., Yan, Y., Jing, L., Yang, B., Tang, H., Yan, A., Liu, M., Song, Y., & Dai, J. (2025). The niacin receptor HCAR2 prevents sleep deprivationinduced cognitive impairment by inhibiting microgliamediated neuroinflammation in mice. International Immunopharmacology, 162, 115174. https://doi.org/10.1016/j.intimp.2025.115174 

[8] Chughtai, S., Doyle, D., Tata, S., Ram, D., & Oymagil, I. (2025). Chemotherapy-induced cognitive impairment: Mechanisms, emerging biomarkers, and therapeutic interventions. Biochemical and Biophysical Research Communications, 779, 152456. https://doi.org/10.1016/j.bbrc.2025.152456 

[9] Du, J., Zhang, A., Li, J., Liu, X., Wu, S., Wang, B., Wang, Y., & Jia, H. (2021). Doxorubicin-induced cognitive impairment: The mechanistic insights. Frontiers in Oncology, 11, 673340. https://doi.org/10.3389/fonc.2021.673340 

[10] First, M. B. (2013). Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. The Journal of Nervous & Mental Disease, 201(9), 727-729. https://doi.org/10.1097/nmd.0b013e3182a2168a 

[11] Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189-198. https://doi.org/10.1016/0022-3956(75)90026-6 

[12] Freitas, S., Simões, M. R., Alves, L., & Santana, I. (2011). Montreal cognitive assessment (MoCA): Normative study for the Portuguese population. Journal of Clinical and Experimental Neuropsychology, 33(9), 989- 996. https://doi.org/10.1080/13803395.2011.589374 

[13] Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., Li, L., Wei, W., & He, J. (2024). Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center, 4(1), 47-53. https://doi.org/10.1016/j.jncc.2024.01.006 

[14] He, M., Liu, Y., Guan, Z., Li, C., & Zhang, Z. (2025). Neuroimaging insights into lung disease-related brain changes: From structure to function. Frontiers in Aging Neuroscience, 17, 1550319. https://doi.org/10.3389/fnagi.2025.1550319 

[15] Ho, M. H., So, T. W., Fan, C. L., Chung, Y. T., & Lin, C. C. (2024). Prevalence and assessment tools of cancerrelated cognitive impairment in lung cancer survivors: A systematic review and proportional meta-analysis. Supportive Care in Cancer, 32(4), 209. https://doi.org/10.1007/s00520-024-08402-9 

[16] Hou, T., Peng, W., Ho, M. H., Takemura, N., & Lin, C. C. (2024). Factors associated with cancer-related cognitive impairment in patients with lung cancer: A systematic review. European Journal of Oncology Nursing, 71, 102657. https://doi.org/10.1016/j.ejon.2024.102657 

[17] Isenberg-Grzeda, E., Huband, H., & Lam, H. (2017). A review of cognitive screening tools in cancer. Current Opinion in Supportive & Palliative Care, 11(1), 24-31. https://doi.org/10.1097/spc.0000000000000257 

[18] Jaggi, A., Conole, E. L. S., Raisi-Estabragh, Z., Gkontra, P., McCracken, C., Szabo, L., Neubauer, S., Petersen, S. E., Cox, S. R., & Lekadir, K. (2024). A structural heart-brain axis mediates the association between cardiovascular risk and cognitive function. Imaging Neuroscience, 2, imag-2-00063. https://doi.org/10.1162/imag_a_00063 

[19] Jing, Y., & Mao, S. (2025). COPD and cognitive impairment: A review of associated factors and intervention strategies. Frontiers in Psychiatry, 16, 1714708. https://doi.org/10.3389/fpsyt.2025.1714708 

[20] kojaie-Bidgoli, A., Fadayevatan, R., Sharifi, F., Alizadeh-Khoei, M., Vahabi, Z., & Aminalroaya, R. (2022). Applicability of SPMSQ in illiterate outpatients in clinics: The validity and reliability of the Short Portable Mental Status Questionnaire. Applied Neuropsychology: Adult, 29(4), 591-597. https://doi.org/10.1080/23279095.2020.1792909 

[21] Lai, J. S., Butt, Z., Wagner, L., Sweet, J. J., Beaumont, J. L., Vardy, J., Jacobsen, P. B., Shapiro, P. J., Jacobs, S. R., & Cella, D. (2009). Evaluating the dimensionality of perceived cognitive function. Journal of Pain and Symptom Management, 37(6), 982-995. https://doi.org/10.1016/j.jpainsymman.2008.07.012 

[22] Lange, M., Joly, F., Vardy, J., Ahles, T., Dubois, M., Tron, L., Winocur, G., De Ruite, M. B., & Castel, H. (2019). Cancer-related cognitive impairment: An update on state of the art, detection, and management strategies in cancer survivors. Annals of Oncology, 30(12), 1925- 1940. https://doi.org/10.1093/annonc/mdz410 

[23] Lezak, M. D., Howieson, D. B., Bigler, E. D., & Tranel, D. (2012). Neuropsychological Assessment (5th ed.). Oxford University Press. 

[24] Li, J., Wang, Y., Zhai, M., Qin, M., Zhao, D., Xiang, Q., Shao, Z., Wang, P., Lin, Y., Dong, Y., & Liu, Y. (2024). Risk factors and a nomogram for predicting cognitive frailty in Chinese patients with lung cancer receiving drug therapy: A single-center cross-sectional study. Thoracic Cancer, 15(11), 884-894. https://doi.org/10.1111/1759-7714.15256 

[25] Liu, S., Ni, J., Yan, F., Yin, N., Li, X., Ma, R., Wu, J., Zhou, G., & Feng, J. (2022). Functional changes of the prefrontal cortex, insula, caudate and associated cognitive impairment (chemobrain) in NSCLC patients receiving different chemotherapy regimen. Frontiers in Oncology, 12, 1027515. https://doi.org/10.3389/fonc.2022.1027515 

[26] Luo, J. H., Luo, Y. Y., Fang, Q. H., Ye, Y. X., Liu, S. T., Yang, Z. H., Miao, J. X., & Zhang, L. L. (2023). Status quo and influencing factors of cognitive function in lung cancer patients. Journal of Nursing, 30(18), 1-5. https://doi.org/10.16460/j.issn1008-9969.2023.18.001 

[27] Luo, Y., Yang, X., & Wang, L. (2025). Prevalence and influencing factors of cognitive impairment in lung cancer patients undergoing chemotherapy. West China Medical Journal, 40(5), 722-727. https://doi.org/10.7507/1002-0179.202412096 

[28] Ma, H., Mu, X., Jin, Y., Luo, Y., Wu, M., & Han, Z. (2024). Multimorbidity, lifestyle, and cognitive function: A cross-cultural study on the role of diabetes, cardiovascular disease, cancer, and chronic respiratory diseases. Journal of Affective Disorders, 362, 560-568. https://doi.org/10.1016/j.jad.2024.07.053 

[29] Mahmoud, A. M. A., Mantawy, E. M., Wahdan, S. A., Ammar, R. M., & El-Demerdash, E. (2023). Vildagliptin restores cognitive function and mitigates hippocampal neuronal apoptosis in cisplatin-induced chemobrain: Imperative roles of AMPK/Akt/CREB/BDNF signaling cascades. Biomedecine & Pharmacotherapie, 159, 114238. https://doi.org/10.1016/j.biopha.2023.114238 

[30] Morris, G., Berk, M., Walder, K., & Maes, M. (2015). Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Medicine, 13(1), 28. https://doi.org/10.1186/s12916-014-0259-2 

[31] Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695-699. https://doi.org/10.1111/j.1532- 5415.2005.53221.x 

[32] Pfeiffer, E. (1975). A short portable mental status questionnaire for the assessment oforganic brain deficit in elderly patients. Journal of the American Geriatrics Society, 23(10), 433-441. https://doi.org/10.1111/j.1532-5415.1975.tb00927.x 

[33] Qin, Y., Pan, Y., & Sun, Z. (2023). Difference of effect mechanism of sex hormone on learning and memory ability between sexes. Journal of Modern Medicine & Health, 39(1). 

[34] Raza, A., Saleem, S., Imran, S., Rahman, S., Haroon, M., Razzaq, A., Hussain, A., Iqbal, J., & Sathian, B. (2025). From metabolic dysregulation to neurodegenerative pathology: The role of hyperglycemia, oxidative stress, and blood-brain barrier breakdown in T2Ddriven Alzheimer's disease. Metabolic Brain Disease, 40 (7), 276. https://doi.org/10.1007/s11011-025-01700-z 

[35] Reitan, R. M. (1958). Validity of the trail making test as an indicator oforganic brain damage. Perceptual and Motor Skills, 8(3), 271-276. https://doi.org/10.2466/pms.8.7.271-276 

[36] Silberfarb, P. M. (1983). Chemotherapy and cognitive defects in cancer patients. Annual Review of Medicine, 34, 35-46. https://doi.org/10.1146/annurev.me.34.020183.000343 

[37] Soria-Comes, T., Palomar-Abril, V., Martín Ureste, M., García Sánchez, J., Marco Buades, J. E., Fernández Llavador, M. J., López Gabaldón, A., González Jurado, M., & Maestu Maiques, I. C. (2020). Cognitive impairment is related to a reduced count of T-lymphocytes in older patients diagnosed with non-small cell lung cancer (NSCLC). Translational Cancer Research, 9(11), 6857-6866. https://doi.org/10.21037/tcr-20-1997 

[38] Takemura, N., Ho, M. H., Cheung, D. S. T., & Lin, C. C. (2022). Factors associated with perceived cognitive impairment in patients with advanced lung cancer: A cross-sectional analysis. Supportive Care in Cancer, 30 (11), 9607-9614. https://doi.org/10.1007/s00520-022-07377-9 

[39] Tang, Q., & Gong, Y. (1992). Development of Changsha norms of Benton visual retention test. Chinese Mental Health Journal, (3), 121-124, 142-143. https://d.wanfangdata.com.cn/periodical/QK000005104347 

[40] Teigão, F. C. M., de Lima Moser, A. D., & Fidalski, S. Z. K. (2024). Evaluation of the psychometric properties of the Brazilian version of the Short Portable Mental Status Questionnaire (SPMSQ) by Pfeiffer. Revista Brasileira de Geriatria e Gerontologia, 27, e230277. https://doi.org/10.1590/1981-22562024027.230277.en 

[41] van Baal, T. L., Köhler, S., Koster, A., Meertens, R. M., Bosma, H., Schram, M. T., Jansen, J. F. A., Simons, S. O., de Galan, B. E., Eussen, S. J. P. M., Janssen, N., & Deckers, K. (2026). The association between sleep parameters, cognitive functioning, and markers of brain morphology: The Maastricht Study. Sleep, 49(3), zsaf218. https://doi.org/10.1093/sleep/zsaf218 

[42] Wagner, L. I., Sweet, J. J., Butt, Z., Lai, J. S., & Cella, D. (2009). Measuring patient self-reported cognitive function: Development of the functional assessment of cancer therapy-cognitive function instrument. Journal of Supportive Oncology, 7(6), W32-W39. https://www.researchgate.net/publication/284687199_Measuring_patient_self-reported_cognitive_function_Development_of_the_Functional_Assessment_of_Cancer_Therapy- Cognitive_Function_Instrument 

[43] Wefel, J. S., Kesler, S. R., Noll, K. R., & Schagen, S. B. (2015). Clinical characteristics, pathophysiology, and management of noncentral nervous system cancerrelated cognitive impairment in adults. CA: A Cancer Journal for Clinicians, 65(2), 123-138. https://doi.org/10.3322/caac.21258 

[44] Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011). International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet Oncology, 12 (7), 703-708. https://doi.org/10.1016/S1470-2045(10)70294-1 

[45] Wei, M., Shi, J., Li, T., Ni, J., Zhang, X., Li, Y., Kang, S., Ma, F., Xie, H., Qin, B., Fan, D., Zhang, L., Wang, Y., & Tian, J. (2018). Diagnostic accuracy of the Chinese version of the trail-making test for screening cognitive impairment. Journal of the American Geriatrics Society, 66(1), 92-99. https://doi.org/10.1111/jgs.15135 

[46] Wu, X., Chen, G., Li, Q., Tang, H., & Shen, H. (2025). Prevalence and predictors of chemotherapy-related cognitive impairment in elderly lung cancer patients: A cross-sectional study. Brain and Behavior, 15(6), e70594. https://doi.org/10.1002/brb3.70594 

[47] Xu, X. Z., Chen, X., Zheng, R., Huang, G. H., Wang, Z. Z., Lv, X. Q., Huang, M., & Hong, J. F. (2026). Perceived cognitive impairment in patients newly diagnosed with lung cancer: A cross-sectional study. Respiratory Medicine, 253, 108699. https://doi.org/10.1016/j.rmed.2026.108699 

[48] Yang, G., & Hegde, U. P. (2024). Cognitive symptoms in patients with cancer receiving PD-1/PD-L1 checkpoint inhibitors: Insights from a cross-sectional pilot study. Journal of Clinical Oncology, 42(16_suppl), 12094. https://doi.org/10.1200/jco.2024.42.16_suppl.12094 

[49] Ye, L., Xu, X., Qi, W., Chen, F., & Xia, G. (2024). Risk factors for cancer-related cognitive impairment among individuals with lung cancer: A systematic review and meta-analysis. Supportive Care in Cancer, 32(10), 663. https://doi.org/10.1007/s00520-024-08873-w 

[50] Zeiser, R., & Prinz, M. (2023). Immune checkpoint inhibitor induced neurocognitive deficits in patients. Brain Communications, 5(3), fcad186. https://doi.org/10.1093/braincomms/fcad186 

[51] Zeng, H., Hendriks, L. E. L., Belderbos, J., Brandts, L., Compter, I., Dubois, L., Holt, M. G., Houben, R., Schagen, S., Zhang, X., Prezzemolo, T., & De Ruysscher, D. (2024). Association of serum biomarkers with neurocognitive decline after PCI in small cell lung cancer: An exploratory study of the phase III NCT01780675 trial. Clinical Lung Cancer, 25(7), 653-659.e1. https://doi.org/10.1016/j.cllc.2024.08.008 

[52] Zhou, W., Xie, X., Hu, J., Wang, M., Hu, X., Shi, L., Zhou, C., & Sun, X. (2024). Relationship between microstructural alterations and cognitive decline after whole-brain radiation therapy for brain metastases: An exploratory whole-brain MR analysis based on neurite orientation dispersion and density imaging. Journal of Magnetic Resonance Imaging, 59(1), 242-252. https://doi.org/10.1002/jmri.28781 

[53] Zeng, H., Hendriks, L. E. L., Belderbos, J., Brandts, L., Compter, I., Dubois, L., Holt, M. G., Houben, R., Schagen, S., Zhang, X., Prezzemolo, T., & De Ruysscher, D. (2024). Association of serum biomarkers with neurocognitive decline after PCI in small cell lung cancer: An exploratory study of the phase III NCT01780675 trial. Clinical Lung Cancer, 25(7), 653-659.e1. https://doi.org/10.1016/j.cllc.2024.08.008